The Technical Field "炎症" had 18 patent application filings in the most recent period (2023-01-01 to 2023-02-28). This is a significantly decreased of -226 filings (-92.6%) over 244 they had in the same period of the previous year (2022-01-01 to 2022-02-28).
The highest number of filings in 2016 with 2,526 cases, and their lowest number in 2022 with 1,472 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 10,397 cases in total) is 1,733, and the median is 2,043. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 1,733 patents |
Std Dev | 799 |
COV | 0.5 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
Year | Cases | YOY |
---|---|---|
2022 year | 1,472 cases | -30.6 % |
2021 year | 2,122 cases | +8.04 % |
2020 year | 1,964 cases | -18.30 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 炎症 for the period of the last 10 years (2014-01-01 to 2024-10-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 炎症, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 炎症 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 20,046 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
A patent aanlysis report on the following synonyms was found in the technical term "炎症".
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 炎症 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 12 cases, followed by ジェネンテックインコーポレイテッド with 11 cases.
Name | Cases |
---|---|
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 12 cases |
ジェネンテックインコーポレイテッド | 11 cases |
ノバルティスアーゲー | 10 cases |
バーテックスファーマシューティカルズインコーポレイテッド | 8 cases |
エフホフマン-ラロシュアーゲー | 5 cases |
ブリストル-マイヤーズスクイブカンパニー | 1 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 1 cases |
Comparing the number of applications of each company, ブリストル-マイヤーズスクイブカンパニー has the highest number of joint applications in the last for the target period (2014 to 2024) with 242 cases, followed by ノバルティスアーゲー with 201 cases.
Name | Cases |
---|---|
ブリストル-マイヤーズスクイブカンパニー | 242 cases |
ノバルティスアーゲー | 201 cases |
エフホフマン-ラロシュアーゲー | 180 cases |
ジェネンテックインコーポレイテッド | 175 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 130 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 109 cases |
武田薬品工業株式会社 | 100 cases |
バーテックスファーマシューティカルズインコーポレイテッド | 51 cases |
メルク・シャープ・アンド・ドーム・コーポレーション | 34 cases |
グラクソグループリミテッド | 5 cases |
メルク・シャープ・エンド・ドーム・コーポレイション | 1 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 炎症 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 12 cases, followed by ジェネンテックインコーポレイテッド with 11 cases.
Name | Cases |
---|---|
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 12 cases |
ジェネンテックインコーポレイテッド | 11 cases |
ノバルティスアーゲー | 10 cases |
エフホフマン-ラロシュアーゲー | 5 cases |
ブリストル-マイヤーズスクイブカンパニー | 1 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 1 cases |
Among the top coapplicants, ブリストル-マイヤーズスクイブカンパニー has the highest number of joint applications in the last for the target period (2014 to 2024) with 242 cases, followed by ノバルティスアーゲー with 201 cases.
Name | Cases |
---|---|
ブリストル-マイヤーズスクイブカンパニー | 242 cases |
ノバルティスアーゲー | 201 cases |
エフホフマン-ラロシュアーゲー | 180 cases |
ジェネンテックインコーポレイテッド | 175 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 130 cases |
メルクパテントゲゼルシャフトミットベシュレンクテルハフツング | 109 cases |
武田薬品工業株式会社 | 100 cases |
Below is a ranking of the number of JP patent applications by 炎症’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 炎症’s top 7 coapplicants over the last 20 years.
炎症 filed 201 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 89 cases in total) is 14.8, and the median is 15.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 41 cases, and their lowest number in 2022 with 9 cases.
Index | Value |
---|---|
Average | 14.8 patents |
Std Dev | 8.5 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -18.18 % |
2021 year | 11 cases | -45.0 % |
2020 year | 20 cases | -13.04 % |
炎症 filed 180 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 69 cases in total) is 11.5, and the median is 11.0. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 32 cases, and their lowest number in 2022 with 5 cases.
Index | Value |
---|---|
Average | 11.5 patents |
Std Dev | 7.7 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 5 cases | -58.3 % |
2021 year | 12 cases | +20.00 % |
2020 year | 10 cases | -50.0 % |
炎症 filed 130 joint applications with ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 63 cases in total) is 10.5, and the median is 11.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 21 cases, and their lowest number in 2020 with 10 cases.
Index | Value |
---|---|
Average | 10.5 patents |
Std Dev | 5.2 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 12 cases | -20.00 % |
2021 year | 15 cases | +50.0 % |
2020 year | 10 cases | -37.5 % |
炎症 filed 175 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 53 cases in total) is 8.8, and the median is 9.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 43 cases, and their lowest number in 2021 with 8 cases.
Index | Value |
---|---|
Average | 8.8 patents |
Std Dev | 4.2 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 10 cases | +25.00 % |
2021 year | 8 cases | 0 |
2020 year | 8 cases | -46.7 % |
炎症 filed 242 joint applications with ブリストル-マイヤーズスクイブカンパニー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 131 cases in total) is 21.8, and the median is 20.0. The coefficient of variation (standard deviation/mean) is 0.9, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2018 with 54 cases, and their lowest number in 2022 with 1 cases.
Index | Value |
---|---|
Average | 21.8 patents |
Std Dev | 19.0 |
COV | 0.9 |
Year | Cases | YOY |
---|---|---|
2022 year | 1 cases | -94.1 % |
2021 year | 17 cases | -52.8 % |
2020 year | 36 cases | +56.5 % |
The following shows JP patents held by 炎症 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 炎症’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 炎症 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 2 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7185426 "S1P受容体モジュレーターの投与計画" (Invalidation Trial day 2023-07-10) , next is 特許5474043 "(+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用" (Invalidation Trial day 2023-05-31) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許7185426 | S1P受容体モジュレーターの投与計画 | 2023-07-10 |
2 | 特許5474043 | (+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用 | 2023-05-31 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 4 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.0. The most invalidation trial patent is 特許6283440 "逆流性食道炎の再発抑制剤" (1 times) , and the next most invalidation trial patent is 特許6074462 "抗−TNFα抗体の投与方法" (1 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6283440 | 逆流性食道炎の再発抑制剤 | 1 times |
2 | 特許6074462 | 抗−TNFα抗体の投与方法 | 1 times |
3 | 特許6293103 | 自己緩衝タンパク質製剤 | 1 times |
4 | 特許6302529 | 抗−TNFα抗体の投与方法 | 1 times |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 13 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7346010 "外用組成物" (Opposition day 2024-03-19) , next is 特許7275044 "慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品" (Opposition day 2023-11-17) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7346010 | 外用組成物 | 2024-03-19 |
2 | 特許7275044 | 慢性炎症性脱髄性多発神経炎の治療における使用のための免疫グロブリン製品 | 2023-11-17 |
3 | 特許7244922 | 化学修飾された一本鎖RNA編集オリゴヌクレオチド | 2023-09-20 |
4 | 特許7074345 | 一本鎖RNA編集オリゴヌクレオチド | 2022-11-18 |
5 | 特許7057127 | 水中油型乳化組成物 | 2022-10-17 |
6 | 特許7038664 | 操作された腫瘍溶解性ウイルス | 2022-09-15 |
7 | 特許7042699 | 評価方法、毛髪処理剤の選定方法、及び評価支援ツール | 2022-09-01 |
8 | 特許7008337 | ヒト機能性角膜内皮細胞およびその応用 | 2022-08-09 |
9 | 特許6954960 | TNF−α及びIL−6産生抑制剤及びそれを用いた筋肉炎症抑制剤 | 2022-04-26 |
10 | 特許6975516 | 外用組成物、化粧料、経皮吸収促進用組成物、外用組成物における有効成分の経皮吸収性を高める方法、経皮投与型医薬及び点眼用組成物 | 2022-04-14 |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 52 patents Protest from third parties. The average number of Protest is 1.7 times. The most recently Protest patent is 特開2020-158493 "パンテノールを含有する油中水型(W/O型)クリーム" (Protest day 2024-09-18) , next is 特開2024-054301 "シート状細胞培養物の製造方法" (Protest day 2024-09-04) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特開2020-158493 | パンテノールを含有する油中水型(W/O型)クリーム | 2024-09-18 |
2 | 特開2024-054301 | シート状細胞培養物の製造方法 | 2024-09-04 |
3 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-02 |
4 | 特表2023-505246 | 無機物および/またはビタミンならびに多糖を含む製剤、その組成物ならびに前記無機物および/またはビタミンの補充におけるその使用 | 2024-08-22 |
5 | 特開2022-070061 | 外用組成物 | 2024-07-31 |
6 | 特開2022-161358 | トラネキサム酸類含有組成物 | 2024-07-23 |
7 | 特開2023-168547 | 眼科組成物 | 2024-06-26 |
8 | 特開2022-063613 | 水中油型乳化化粧料 | 2024-06-24 |
9 | 特開2021-098756 | 眼科組成物 | 2024-06-12 |
10 | 特開2022-072468 | 皮膚外用剤 | 2024-05-08 |
11 | 特許7513305 | 3次元培養された幹細胞から細胞外小胞体を製造する方法 | 2024-05-02 |
12 | 特表2022-545464 | 微細構造の製造方法 | 2024-04-11 |
13 | 特許7545478 | 環状ジペプチド、プリンヌクレオチド及び/又はアミノ酸とチキンエキスとを含む組成物、その製造方法、並びに、環状ジペプチド、プリンヌクレオチド及び/又はアミノ酸、並びにチキンエキスの使用 | 2024-03-25 |
14 | 特開2023-175938 | 糖代謝改善用組成物 | 2024-03-04 |
15 | 特許7446003 | マカ抽出物及びその用途 | 2024-02-16 |
16 | 特表2023-534047 | オリゴ糖組成物及び使用方法 | 2024-02-07 |
17 | 特許7542530 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-01-30 |
18 | 特表2021-500373 | 線維芽細胞活性化タンパク質α(FAP−α)を標的とする撮像剤および放射線療法用薬剤 | 2024-01-12 |
19 | 特許7564872 | 三環式ジヒドロイミダゾピリミドン誘導体、その調製方法、その医薬組成物及び使用 | 2023-12-25 |
20 | 特開2022-067658 | 皮膚外用クリーム剤 | 2023-10-30 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 91 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.5. The most protest patent is 特許7346010 "外用組成物" (6 times) , and the next most protest patent is 特開2019-014714 "抗炎症組成物" (6 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許7346010 | 外用組成物 | 6 times |
2 | 特開2019-014714 | 抗炎症組成物 | 6 times |
3 | 特許7412869 | 歯肉ケア剤及びそれを含有する歯肉ケア用口腔用組成物 | 5 times |
4 | 特許6847457 | 高圧加工米および該高圧加工米を含む食品用または医薬用組成物 | 5 times |
5 | 特開2020-158493 | パンテノールを含有する油中水型(W/O型)クリーム | 5 times |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 290 patents Inspection from third parties. The average number of Inspection is 1.4 times. The most recently Inspection patent is 特開2024-054301 "シート状細胞培養物の製造方法" (Inspection day 2024-09-24) , next is 特表2024-524458 "トランスグルタミナーゼの阻害剤" (Inspection day 2024-09-19) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特開2024-054301 | シート状細胞培養物の製造方法 | 2024-09-24 |
2 | 特表2024-524458 | トランスグルタミナーゼの阻害剤 | 2024-09-19 |
3 | 特表2021-517895 | HPV関連疾患を処置するための方法 | 2024-09-19 |
4 | 特表2021-533087 | 神経炎症におけるマクロファージコロニー刺激因子1受容体(CSF1R)をイメージングするための陽電子放射断層撮影(PET)放射性トレーサー | 2024-09-13 |
5 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-12 |
6 | 特許7553357 | がんの処置のための組成物および方法 | 2024-09-05 |
7 | 特表2021-521798 | がんに対する組換え型の治療介入 | 2024-09-02 |
8 | 特許7555346 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 | 2024-08-30 |
9 | 特開2022-141699 | 疼痛を治療するためのKV3チャネルのモジュレーター | 2024-08-30 |
10 | 特表2023-518552 | LNP023の結晶形態 | 2024-08-27 |
11 | 特開2020-158493 | パンテノールを含有する油中水型(W/O型)クリーム | 2024-08-21 |
12 | 特表2023-548848 | ループスを処置するための方法および組成物 | 2024-08-14 |
13 | 特開2022-070061 | 外用組成物 | 2024-08-13 |
14 | 特許7564274 | 結合剤 | 2024-08-09 |
15 | 特許7446003 | マカ抽出物及びその用途 | 2024-08-08 |
16 | 特開2023-030014 | チオールイソメラーゼ阻害剤およびその使用 | 2024-08-06 |
17 | 特開2022-088355 | 結合タンパク質及びその使用方法 | 2024-07-29 |
18 | 特開2023-168547 | 眼科組成物 | 2024-07-23 |
19 | 特開2022-081616 | TUSC2免疫療法のための方法および組成物 | 2024-07-11 |
20 | 特開2022-069555 | オキシステロールおよびその使用方法 | 2024-07-03 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 585 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.4. The most inspection patent is 特開2017-149726 "B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特許6283440 "逆流性食道炎の再発抑制剤" (12 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-149726 | B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
2 | 特許6283440 | 逆流性食道炎の再発抑制剤 | 12 times |
3 | 特開2019-014714 | 抗炎症組成物 | 10 times |
4 | 特開2018-070660 | 逆流性食道炎の再発抑制剤 | 9 times |
5 | 特許7346010 | 外用組成物 | 9 times |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 2,853 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特許6778114 "イミド系タンパク質分解モジュレーター及び関連する使用方法" (32 times) , and the next most cited patent is 特許6400738 "補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物" (29 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 32 times |
2 | 特許6400738 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | 29 times |
3 | 特表2018-517454 | 非血管狭窄のための薬物コーティングされたバルーンカテーテル | 28 times |
4 | 特許6688352 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 | 25 times |
5 | 特許6490713 | タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物 | 23 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International